Health In Tech, Inc.
NASDAQ:HITSoftware - Application
+$0.00 today
- Market cap
- $50.13M
- Beta
- 2.94
- P/E (TTM)
- -75.2
- EPS (TTM)
- -$0.01
Volume 0.04M
Average 0.23M
HIT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Health In Tech, Inc.NASDAQ: HIT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $920.4K rose 71.2% year over year, ahead of the -24.7% change in trailing-twelve-month research & development. Sequentially, it rose 331.9% from the prior quarter. Over 3 fiscal years it compounded at +25.5% a year.
Context
- Research & development amounted to 4.7% of revenue in FY2025, down 9.7 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +71.2% holds above the trailing-twelve-month pace of -24.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 1.57M USD
- Year-over-year change
- -44.2%
- 3-year CAGR
- +25.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.57M | -44.2% |
| FY2024 | 2024-12-31 | 2.81M | +40.4% |
| FY2023 | 2023-12-31 | 2M | +152.3% |
| FY2022 | 2022-12-31 | 794.62K | — |
Research & Development vs competitors
How HIT compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -24.7% is the 6th highest of 7, against a peer median of -5.2%.
- Research & development amounts to 5.7% of revenue for HIT, versus a peer median of 12.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LAWRRobot Consulting Co., Ltd. ADS | FY2025 | ¥86.16M JPY | -16.7% | +6.5% | 12.8% |
TEADTeads Holding Co. | LTM Mar 2026 | $40.26M USD | -3.8% | +2.6% | 3.1% |
SVCOSilvaco Group, Inc. Common Stock | LTM Mar 2026 | $33.82M USD | +54.3% | +33.9% | 50.7% |
| LTM Mar 2026 | $30.54M USD | -37.0% | -2.7% | 20.0% | |
| LTM Mar 2026 | $30.29M USD | +19.2% | +12.8% | 8.4% | |
| LTM Mar 2026 | $22.49M USD | -6.6% | +14.7% | 16.1% | |
HITHealth In Tech, Inc. | LTM Mar 2026 | $1.95M USD | -24.7% | +25.5% | 5.7% |
| FY2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding HIT) | — | -5.2% | +9.6% | 12.8% | |
Competitors are the stored peer set for HIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 5.77M | 19.15M | 19.49M | 33.33M |
| Cost of Revenue | 334.19K | 2.3M | 4.05M | 12.39M |
| Gross Profit | 5.44M | 16.85M | 15.44M | 20.94M |
| Gross Margin | 94.2% | 88.0% | 79.2% | 62.8% |
| Research & Development | 794.62K | 2M | 2.81M | 1.57M |
| Selling, General & Admin | 4.44M | 11.46M | 11.64M | 17.84M |
| Operating Expenses | 5.23M | 13.46M | 14.45M | 19.41M |
| Depreciation & Amortization | 0 | 339.3K | 541.14K | 900.58K |
| EBITDA | 205.58K | 3.76M | 1.93M | 2.57M |
| EBITDA Margin | 3.6% | 19.6% | 9.9% | 7.7% |
| Operating Income | 205.58K | 3.38M | 989.9K | 1.53M |
| Operating Margin | 3.6% | 17.7% | 5.1% | 4.6% |
| Interest Income | 0 | 40.86K | 122.89K | 409.92K |
| Interest Expense | 4.57K | 2.05K | 495K | 0 |
| Other Income / Expenses | (4.57K) | 38.81K | (100.9K) | 145.73K |
| Income Before Tax | 201.01K | 3.42M | 889K | 1.67M |
| Pre-Tax Margin | 3.5% | 17.9% | 4.6% | 5.0% |
| Income Tax Expense | 121.27K | 945.24K | 218.52K | 395.33K |
| Net Income | 79.74K | 2.48M | 670.48K | 1.28M |
| Net Margin | 1.4% | 12.9% | 3.4% | 3.8% |
| EPS (Basic) | 0.00 | 0.05 | 0.01 | 0.02 |
| EPS (Diluted) | 0.00 | 0.05 | 0.01 | 0.02 |
| Weighted Avg Shares | 54.07M | 54.07M | 67.05M | 55.84M |
| Weighted Avg Shares (Diluted) | 54.07M | 54.07M | 53.66M | 57.74M |
Health In Tech, Inc.
NASDAQ:HIT
Intrinsic Alpha fair value
Locked
Current Price
$0.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.